| Estimating kinetic parameters from dynamic contrast‐enhanced t1‐weighted MRI of a diffusable tracer: Standardized quantities and symbols PS Tofts, G Brix, DL Buckley, JL Evelhoch, E Henderson, MV Knopp, ... Journal of Magnetic Resonance Imaging: An Official Journal of the …, 1999 | 3872 | 1999 |
| Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging G Brix, W Semmler, R Port, LR Schad, G Layer, WJ Lorenz Journal of computer assisted tomography 15 (4), 621-628, 1991 | 905 | 1991 |
| MR imaging of tumor microcirculation: promise for the new millenium JS Taylor, PS Tofts, R Port, JL Evelhoch, M Knopp, WE Reddick, ... Journal of Magnetic Resonance Imaging: An Official Journal of the …, 1999 | 284 | 1999 |
| Dynamic contrast‐enhanced MRI using Gd‐DTPA: interindividual variability of the arterial input function and consequences for the assessment of kinetics in tumors RE Port, MV Knopp, G Brix Magnetic Resonance in Medicine: An Official Journal of the International …, 2001 | 207 | 2001 |
| Multicompartment analysis of gadolinium chelate kinetics: blood‐tissue exchange in mammary tumors as monitored by dynamic MR imaging RE Port, MV Knopp, U Hoffmann, S Milker‐Zabel, G Brix Journal of Magnetic Resonance Imaging: An Official Journal of the …, 1999 | 207 | 1999 |
| Metabolites of 5-Fluorouracil in Plasma and Urine, as Monitored by 19F Nuclear Magnetic Resonance Spectroscopy, for Patients Receiving Chemotherapy with or … WE Hull, RE Port, R Herrmann, B Britsch, W Kunz Cancer research 48 (6), 1680-1688, 1988 | 156 | 1988 |
| Quantitative analysis of enzyme-altered foci in rat hepatocarcinogenesis experiments—I. Single agent regimen SH Moolgavkar, EG Luebeck, M de Gunst, RE Port, M Schwarz Carcinogenesis 11 (8), 1271-1278, 1990 | 141 | 1990 |
| Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies A Bustad, D Terziivanov, R Leary, R Port, A Schumitzky, R Jelliffe Clinical Pharmacokinetics 45, 365-383, 2006 | 136 | 2006 |
| Pharmacokinetic Analysis of 5-[18F]Fluorouracil Tissue Concentrations Measured with Positron Emission Tomography in Patients with Liver Metastases from … J Kissel, G Brix, ME Bellemann, LG Strauss, A Dimitrakopoulou-Strauss, ... Cancer research 57 (16), 3415-3423, 1997 | 97 | 1997 |
| Quantitative aspects of chemical carcinogenesis and tumor promotion in liver. HW Kunz, HA Tennekes, RE Port, M Schwartz, D Lorke, G Schaude Environmental Health Perspectives 50, 113-122, 1983 | 91 | 1983 |
| A population model for the leukopenic effect of etoposide MO Karlsson, RE Port, MJ Ratain, LB Sheiner Clinical Pharmacology & Therapeutics 57 (3), 325-334, 1995 | 88 | 1995 |
| A dose‐response study on urethane carcinogenesis in rats and mice D Schmähl, R Port, J Wahrendorf International Journal of Cancer 19 (1), 77-80, 1977 | 83 | 1977 |
| Relative importance of dose, body surface area, sex, and age for 5-fluorouracil clearance RE Port, B Daniel, RW Ding, R Herrmann Oncology 48 (4), 277-281, 1991 | 78 | 1991 |
| Pharmacokinetics and whole-body distribution of the new chemotherapeutic agent β-D-glucosylisophosphoramide mustard and its effects on the incorporation of [methyl-3H … J Stüben, R Port, B Bertram, U Bollow, WE Hull, M Schaper, J Pohl, ... Cancer chemotherapy and pharmacology 38, 355-365, 1996 | 47 | 1996 |
| Maximizing tumour exposure to anti‐neuropilin‐1 antibody requires saturation of non‐tumour tissue antigenic sinks in mice D Bumbaca, H Xiang, CA Boswell, RE Port, SL Stainton, EE Mundo, ... British journal of pharmacology 166 (1), 368-377, 2012 | 45 | 2012 |
| Population pharmacokinetics of piritramide in surgical patients T Bouillon, D Kietzmann, R Port, I Meineke, A Hoeft The Journal of the American Society of Anesthesiologists 90 (1), 7-15, 1999 | 45 | 1999 |
| An automated method for nonparametric kinetic analysis of clinical DCE‐MRI data: application to glioblastoma treated with bevacizumab GZ Ferl, L Xu, M Friesenhahn, LJ Bernstein, DP Barboriak, RE Port Magnetic Resonance in Medicine 63 (5), 1366-1375, 2010 | 40 | 2010 |
| 18F-FDG PET as a surrogate biomarker in non–small cell lung cancer treated with erlotinib: newly identified lesions are more informative than standardized uptake value T Bengtsson, RJ Hicks, A Peterson, RE Port Journal of Nuclear Medicine 53 (4), 530-537, 2012 | 35 | 2012 |
| Erythropoietin dosing in children with chronic kidney disease: based on body size or on hemoglobin deficit? RE Port, O Mehls Pediatric nephrology 24 (3), 435-437, 2009 | 35 | 2009 |
| Noncompartmental kinetic analysis of DCE‐MRI data from malignant tumors: Application to glioblastoma treated with bevacizumab RE Port, LJ Bernstein, DP Barboriak, L Xu, TPL Roberts, N van Bruggen Magnetic resonance in medicine 64 (2), 408-417, 2010 | 34 | 2010 |
Geoff JM ParkerProfessor of Healthcare Engineering, Imaging, and Enterprise, University College LondonAdresse e-mail validée de ucl.ac.uk
